Boston Scientific Corporation
Boston Scientific Corporation (BSX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bsx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Boston Scientific Corporation (BSX) measures how much investors pay for each dollar of the company's trailing earnings. BSX's current PE ratio of 20.35x is calculated by dividing its stock price of $48.70 by its TTM earnings per share of $2.39. −68.7% discount vs 5Y avg 65.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%55.4x
MedianQ3 · 75%326.6x
Max
At 20.35x, BSX's current P/E is lower than in 20% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Boston Scientific CorporationYou BSX | $72.4B | 20.35x | -22.4% | $2.39 |
 Abbott Laboratories ABT | $157.6B | 33.55x | +27.8% | $3.73 |
 Amgen Inc. AMGN | $186.6B | 22.84x | -13.0% | $14.33 |
 Danaher Corporation DHR | $129.9B | 44.80x | +70.7% | $5.11 |
 Gilead Sciences, Inc. GILD | $159.0B | 17.94x | -31.6% | $6.84 |
 HCA Healthcare, Inc. HCA | $80.2B | 15.88x | -39.5% | $29.40 |
 McKesson Corporation MCK | $92.2B | 22.46x | -14.4% | $38.53 |
Industry Average 6 peers with valid PE | — | 26.24x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 48.91x | $1.95 | -31.0% | |
2024-12-31 FY2024 | 70.89x | $1.26 | +34.4% | |
2023-12-31 FY2023 | 52.73x | $1.10 | -44.4% | |
2022-12-31 FY2022 | 94.83x | $0.49 | +63.2% | |
2021-12-31 FY2021 | 58.10x | $0.73 | — | |
2020-12-31 FY2020 | — | $-0.06 | — | |
2019-12-31 FY2019 | 13.39x | $3.38 | -54.2% | |
2018-12-31 FY2018 | 29.21x | $1.21 | -91.1% | |
2017-12-31 FY2017 | 326.58x | $0.08 | +285.9% | |
2016-12-31 FY2016 | 84.63x | $0.26 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Boston Scientific Corporation (BSX) measures how much investors pay for each dollar of the company's trailing earnings. BSX's current PE ratio of 20.35x is calculated by dividing its stock price of $48.70 by its TTM earnings per share of $2.39.
Frequently asked questions
BSX pe ratio · 6 questionsBSX's current PE ratio is 20.35x as of 2026-06-08, based on a stock price of $48.70 and TTM EPS of $2.39. Data sourced from Financial Modeling Prep via BSX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Boston Scientific Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08